Download Cancer is personal, your treatment should be too What makes

Will my insurance cover the test?
TheraPrint® is not currently covered by health
insurance plans. You will be responsible for all cost
associated with the TheraPrint® test.
What if I don’t have insurance or my
health plan doesn’t cover it?
Molecular Tumor Profiling
for Breast or Colorectal
Cancer
Agendia is a compassionate company offering a wide
range of financial assistance programs. Please contact
Agendia’s billing department at 888-363-7868 or
[email protected].
What makes
personalized
therapy different?
US: 22 Morgan | Irvine | CA | 92618 | Ph. 888.321.2732
Fax 866.756.7548 | [email protected] | www.agendia.com
Outside US: Agendia NV | Science Park 406 | 1098 XH Amsterdam
The Netherlands | Ph. +31 (0) 462 1500 | [email protected]
www.agendia.com
©Copyright 2013 Agendia. All rights reserved.
M-USA-017-V2
Cancer is personal,
your treatment
should be too
If you are reading this it is likely that you or a loved
one has been touched by cancer. While this is a
frightening diagnosis, the good news is that cancer
management is changing due to increased knowledge
and understanding of genes, genetics and genomics
(the underlying biology of a tumor). This information
is gathered through laboratory [genomic] testing
and the analysis enables physicians to select more
specific or targeted therapies with the least amount
of side effects for every individual patient.
What is the difference between Genomic and
Genetic testing?
Most commonly, the words “genetic” and “genomic”
are often used interchangeably. However, in cancer
diagnostic testing, these terms have specific meanings.
Genetic testing is often used when speaking about
your genes and hereditary traits or diseases and assess
your risk of getting cancer, whereas genomic tests are
specific to the cancer tumor’s genes and assess how
the tumor is behaving. Molecular tumor profiling
provides you and your doctor information on how this
specific cancer tumor is behaving and how the tumor
may respond to treatment. This means your cancer
treatment is guided by the biological profile of your
unique tumor.
Why is Genomic testing important?
Personalized medicine is the practice of using information specific to you (such as your tumor’s genomic
profile) to personalize medical care and make it more
individualized, precise and potentially more effective.
It is also sometimes called Precision Medicine.
What is TheraPrint® Molecular Tumor Profiling
for Breast or Colorectal Cancer?
TheraPrint® was designed to complement traditional
cancer treatment decision-making tools by identifying
unique molecular characteristics of your tumor.
TheraPrint® provides a genomic fingerprint of your
tumor and matches it with potential targeted therapies.
The test enables your oncologist to incorporate the
latest scientific and medical data into your treatment
decision.
The assessment of a patient’s specific tumor biology plays
a particular important role for patients who have failed
standard first line therapy and may benefit from treatment
that is more tailored toward their individual tumor. Patients
may also find that they may be eligible for novel new
therapies by joining a clinical trial. Information provided
by TheraPrint® puts you and your physician in a position
to make the best treatment decision possible for you.
What will the test results show?
There is one more thing to keep in mind: not only could
treatment guided by molecular profiling give more
patients a better chance for survival, it can keep patients
and their health insurance carrier from wasting both time
and money on treatments that aren’t working.
Each biomarker is profiled with a short clinical relevance
statement, a description of how gene activity and/or
mutation are linked to response or resistance of the
associated drugs. More detailed information on the
TheraPrint® biomarkers and related clinical references are
available to your physician.
Is TheraPrint® right for me?
TheraPrint® is appropriate for people with breast or
colorectal cancer. It is an important option for patients in
several situations:
• Your doctor is choosing between multiple
recommended treatments
• Standard or first-line treatment options are not working
• Your cancer is particularly aggressive or rare or has
limited treatment options for other reasons
The result report includes information on the DNA
mutations and/or activity changes of the RNA biomarkers
in your tumor. Each biomarker is classified related to the
drug class for which it is has meaning. For example, the
activity of the ESR (estrogen receptor) gene is a very
important indicator of your tumor’s ability to respond to
the common breast cancer drug tamoxifen.